Welcome to our dedicated page for Else Nutrition Holdings SEC filings (Ticker: BABYD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Else Nutrition Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Else Nutrition Holdings's regulatory disclosures and financial reporting.
Else Nutrition Holdings Inc., a British Columbia-based health care/biotechnology corporation with annual revenue between $1,000,001 and $5,000,000, filed an amended notice of an exempt private securities offering under Regulation D Rule 506(b).
The offering covers equity, debt, and convertible securities and warrants issued under a Convertible Security Funding Agreement dated November 23, 2025, each convertible or exercisable into common shares. With a first sale date of November 24, 2025, the company reports $1,235,200 sold and $1,208,499 remaining to be sold, with the remaining amount including the aggregate exercise price of the warrants. No finders’ fees are payable, and a portion of net proceeds may be used for general working capital, including ordinary-course payments to officers and directors, though proceeds are not specifically earmarked for such payments.